Garrison Bradford & Associates Inc. Sells 1,400 Shares of Abbott Laboratories (ABT)

Garrison Bradford & Associates Inc. decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 25.9% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,000 shares of the healthcare product maker’s stock after selling 1,400 shares during the quarter. Garrison Bradford & Associates Inc.’s holdings in Abbott Laboratories were worth $228,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Rowland & Co. Investment Counsel ADV bought a new stake in Abbott Laboratories during the fourth quarter valued at about $102,000. Heritage Trust Co boosted its position in Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after purchasing an additional 200 shares in the last quarter. Tributary Capital Management LLC bought a new stake in Abbott Laboratories during the third quarter valued at about $106,000. Thompson Davis & CO. Inc. boosted its position in Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after purchasing an additional 370 shares in the last quarter. Finally, Motco boosted its position in Abbott Laboratories by 213.7% during the second quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after purchasing an additional 1,962 shares in the last quarter. 70.01% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider Alejandro D. Wellisch sold 2,153 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total value of $120,266.58. Following the completion of the transaction, the insider now directly owns 10,256 shares in the company, valued at $572,900.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Miles D. White sold 276,886 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total value of $15,065,367.26. Following the completion of the transaction, the chairman now owns 3,677,913 shares of the company’s stock, valued at $200,115,246.33. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 350,592 shares of company stock valued at $19,426,949. Company insiders own 0.76% of the company’s stock.

ABT has been the topic of a number of recent research reports. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. ValuEngine raised Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, November 22nd. BMO Capital Markets raised Abbott Laboratories from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $58.00 to $65.00 in a research report on Tuesday, December 12th. Morgan Stanley raised Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 price objective on the stock in a research report on Tuesday, January 2nd. Finally, JPMorgan Chase & Co. raised Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $60.00 price objective on the stock in a research report on Tuesday, January 2nd. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $65.47.

Shares of Abbott Laboratories (NYSE:ABT) opened at $60.17 on Monday. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 12 month low of $42.31 and a 12 month high of $64.60. The company has a market capitalization of $104,730.00, a PE ratio of 57.86, a price-to-earnings-growth ratio of 1.81 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The company had revenue of $7.59 billion during the quarter, compared to analysts’ expectations of $7.38 billion. During the same period last year, the business posted $0.65 earnings per share. The firm’s revenue was up 42.3% compared to the same quarter last year. equities research analysts predict that Abbott Laboratories will post 2.86 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 1.86%. Abbott Laboratories’s payout ratio is 107.69%.

COPYRIGHT VIOLATION WARNING: “Garrison Bradford & Associates Inc. Sells 1,400 Shares of Abbott Laboratories (ABT)” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2018/02/19/garrison-bradford-associates-inc-sells-1400-shares-of-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Garrison Bradford & Associates Inc. Sells 1,400 Shares of Abbott Laboratories (ABT)

Garrison Bradford & Associates Inc. trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 25.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,000 shares of the healthcare product maker’s stock after selling 1,400 shares during the period. Garrison Bradford & Associates Inc.’s holdings in Abbott Laboratories were worth $228,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Vanguard Group Inc. raised its holdings in Abbott Laboratories by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock valued at $6,308,944,000 after buying an additional 3,241,063 shares during the period. Capital Research Global Investors raised its holdings in Abbott Laboratories by 45.7% during the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock valued at $2,313,334,000 after buying an additional 14,918,038 shares during the period. Northern Trust Corp raised its holdings in Abbott Laboratories by 3.1% during the 2nd quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock valued at $1,305,942,000 after buying an additional 809,732 shares during the period. Dimensional Fund Advisors LP raised its holdings in Abbott Laboratories by 28.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock valued at $569,830,000 after buying an additional 2,606,404 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in Abbott Laboratories by 7.7% during the 2nd quarter. Alliancebernstein L.P. now owns 11,607,121 shares of the healthcare product maker’s stock valued at $564,222,000 after buying an additional 830,610 shares during the period. 70.01% of the stock is currently owned by institutional investors and hedge funds.

In other news, EVP Stephen R. Fussell sold 13,313 shares of the stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $62.84, for a total transaction of $836,588.92. Following the transaction, the executive vice president now owns 152,343 shares of the company’s stock, valued at approximately $9,573,234.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian J. Blaser sold 27,733 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $62.26, for a total value of $1,726,656.58. Following the transaction, the insider now directly owns 156,587 shares in the company, valued at approximately $9,749,106.62. The disclosure for this sale can be found here. Insiders have sold a total of 350,592 shares of company stock worth $19,426,949 in the last three months. Corporate insiders own 0.76% of the company’s stock.

Shares of Abbott Laboratories (NYSE ABT) opened at $60.17 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 52 week low of $42.31 and a 52 week high of $64.60. The firm has a market capitalization of $104,730.00, a price-to-earnings ratio of 57.86, a price-to-earnings-growth ratio of 1.81 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The business had revenue of $7.59 billion for the quarter, compared to the consensus estimate of $7.38 billion. During the same quarter in the prior year, the company earned $0.65 EPS. The business’s revenue was up 42.3% compared to the same quarter last year. sell-side analysts expect that Abbott Laboratories will post 2.86 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.86%. Abbott Laboratories’s payout ratio is 107.69%.

Several research firms recently weighed in on ABT. Barclays increased their price target on Abbott Laboratories from $66.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Guggenheim restated a “buy” rating and set a $72.00 price target on shares of Abbott Laboratories in a report on Thursday, January 25th. Royal Bank of Canada restated a “buy” rating and set a $67.00 price target on shares of Abbott Laboratories in a report on Thursday, January 25th. Leerink Swann restated a “market perform” rating and set a $68.00 price target (up previously from $60.00) on shares of Abbott Laboratories in a report on Thursday, January 25th. Finally, Citigroup increased their price target on Abbott Laboratories from $59.00 to $64.00 and gave the company a “neutral” rating in a report on Tuesday, January 30th. Eight equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $65.47.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thelincolnianonline.com/2018/02/19/garrison-bradford-associates-inc-sells-1400-shares-of-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply